Catalyst Calendar
Scope

Tue, Jul 7, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,

Trial Start • Phase 3Trial initiation Tue, Jul 7, 2026axsome.com

Fri, Jun 26, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol

Trial Start • Phase 3Trial initiation Fri, Jun 26, 2026axsome.com

Thu, Jun 18, 2026

1 updates

Mon, Jun 15, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting

Presentation / Abstract • Phase 3Poster presentation Mon, Jun 15, 2026, 10:00 AM ETaxsome.com

Thu, Jun 4, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO ® data at the Americal Headache Society (AHS) 68th Annual

Presentation / Abstract • Phase 3Poster presentation Thu, Jun 4, 2026, 6:00 PM ETaxsome.com

Wed, Jun 3, 2026

1 updates

Mon, Jun 1, 2026

1 updates

Wed, May 27, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in June: William

axsome.com

Tue, May 26, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY ® data in major depressive disorder at the American Society of

Presentation / AbstractASCP poster presentation Wed, May 27, 2026, 11:45 AM ETaxsome.com

Thu, May 7, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community.

axsome.com

Tue, May 5, 2026

1 updates
AXSM
7:00 AM

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in May: BofA

axsome.com

Mon, May 4, 2026

1 updates

Fri, May 1, 2026

1 updates

Thu, Apr 30, 2026

1 updates
AXSM
2:06 PM

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in agitation associated with dementia due to Alzheimer’s disease has been established

axsome.com